Fig. 1. Mebendazole (MBZ) inhibits proliferation and induces apoptosis of CML cells.
(A–C) Dose-response curve for IM and MBZ in K562 and K562/G01 using CCK-8 assay after incubation for 48 h. (D) Dose-response curve for MBZ in bone marrow stromal cell line HS-5 using CCK-8 assay after incubation for 48 h. (E) The cell proliferative activity of CML cells treated with MBZ for 7 days was assessed using a colony formation assay. The scale bar represents 25 μm. (F) The colony formation rate was calculated and statistically analyzed. (G) The apoptosis levels of CML cells were evaluated using annexin-V-FITC/PI labeling and FCM after MBZ treatment for 24 h. (H) The cell apoptosis rate was analyzed based on the FCM results. (I) The protein expression levels of PARP, Caspase-3, and their corresponding cleaved bands were measured using a western blot. (J, K) The expression levels of Bax, Bcl-2, and Bcl-XL were detected by western blot, and the ratio of Bcl-2/Bax was calculated. The values are the mean and SD of three independent experiments. CML, chronic myeloid leukemia; IM, imatinib; PI, propidium iodide; FCM, flow cytometry; ns, no significance. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 vs. the control group.
© Korean J Physiol Pharmacol
